BioXcel Total Assets vs Total Current Assets Analysis

BTAI Stock

USD 0.41 0.04 8.89%

BioXcel Therapeutics financial indicator trend analysis is way more than just evaluating BioXcel Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioXcel Therapeutics is a good investment. Please check the relationship between BioXcel Therapeutics Total Assets and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

Total Assets vs Total Current Assets

Total Assets vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioXcel Therapeutics Total Assets account and Total Current Assets. At this time, the significance of the direction appears to have totally related.

The correlation between BioXcel Therapeutics' Total Assets and Total Current Assets is 1.0. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of BioXcel Therapeutics, assuming nothing else is changed. The correlation between historical values of BioXcel Therapeutics' Total Assets and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of BioXcel Therapeutics are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Total Assets i.e., BioXcel Therapeutics' Total Assets and Total Current Assets go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Assets

Total assets refers to the total amount of BioXcel Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioXcel Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from BioXcel Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioXcel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.The BioXcel Therapeutics' current Selling General Administrative is estimated to increase to about 66.7 M, while Issuance Of Capital Stock is projected to decrease to under 21.1 M.

BioXcel Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant Equipment	Other Current Liab	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Short Long Term Debt Total	Net Debt	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt
Total Assets		0.72	0.79	0.81	0.81	0.46	1.0	0.64	0.8	0.93	0.88	0.54	0.9	0.65	0.9	0.89	0.68	0.37	-0.84	0.34	1.0	0.83	0.79	0.74	0.98	-0.13
Total Current Liabilities	0.72		0.14	0.9	0.96	0.94	0.72	0.64	0.93	0.59	0.73	0.95	0.65	0.31	0.85	0.84	0.73	0.9	-0.23	-0.06	0.73	0.91	0.96	0.74	0.59	-0.62
Total Stockholder Equity	0.79	0.14		0.38	0.3	-0.19	0.79	0.41	0.34	0.79	0.65	-0.07	0.73	0.68	0.52	0.54	0.37	-0.28	-1.0	0.48	0.77	0.4	0.27	0.46	0.88	0.4
Common Stock Shares Outstanding	0.81	0.9	0.38		0.92	0.75	0.81	0.71	0.91	0.75	0.81	0.82	0.77	0.49	0.88	0.91	0.82	0.69	-0.46	0.0	0.8	0.95	0.91	0.83	0.74	-0.4
Other Stockholder Equity	0.81	0.96	0.3	0.92		0.85	0.81	0.65	0.88	0.77	0.79	0.91	0.76	0.44	0.88	0.89	0.73	0.81	-0.38	-0.02	0.83	0.95	1.0	0.75	0.7	-0.63
Total Liab	0.46	0.94	-0.19	0.75	0.85		0.46	0.44	0.81	0.33	0.48	0.96	0.37	0.06	0.68	0.63	0.55	1.0	0.1	-0.15	0.48	0.76	0.86	0.54	0.31	-0.75
Total Current Assets	1.0	0.72	0.79	0.81	0.81	0.46		0.64	0.8	0.93	0.88	0.54	0.89	0.65	0.9	0.88	0.68	0.38	-0.84	0.35	1.0	0.83	0.79	0.74	0.98	-0.13
Property Plant Equipment	0.64	0.64	0.41	0.71	0.65	0.44	0.64		0.62	0.63	0.92	0.63	0.74	0.33	0.7	0.89	0.75	0.37	-0.46	-0.06	0.63	0.77	0.64	0.86	0.6	-0.23
Other Current Liab	0.8	0.93	0.34	0.91	0.88	0.81	0.8	0.62		0.62	0.73	0.8	0.7	0.45	0.88	0.85	0.7	0.76	-0.42	0.1	0.79	0.9	0.87	0.75	0.73	-0.31
Net Tangible Assets	0.93	0.59	0.79	0.75	0.77	0.33	0.93	0.63	0.62		0.86	0.48	0.89	0.65	0.8	0.84	0.66	0.25	-0.83	0.24	0.93	0.8	0.76	0.73	0.93	-0.2
Property Plant And Equipment Net	0.88	0.73	0.65	0.81	0.79	0.48	0.88	0.92	0.73	0.86		0.64	0.88	0.49	0.88	0.97	0.77	0.4	-0.7	0.18	0.88	0.86	0.78	0.85	0.85	-0.23
Accounts Payable	0.54	0.95	-0.07	0.82	0.91	0.96	0.54	0.63	0.8	0.48	0.64		0.52	0.14	0.74	0.76	0.68	0.94	-0.02	-0.21	0.56	0.85	0.92	0.68	0.39	-0.79
Non Current Assets Total	0.9	0.65	0.73	0.77	0.76	0.37	0.89	0.74	0.7	0.89	0.88	0.52		0.83	0.72	0.88	0.69	0.28	-0.78	0.0	0.9	0.79	0.74	0.71	0.88	-0.16
Non Currrent Assets Other	0.65	0.31	0.68	0.49	0.44	0.06	0.65	0.33	0.45	0.65	0.49	0.14	0.83		0.33	0.51	0.37	-0.01	-0.7	-0.15	0.64	0.47	0.42	0.36	0.68	0.11
Other Current Assets	0.9	0.85	0.52	0.88	0.88	0.68	0.9	0.7	0.88	0.8	0.88	0.74	0.72	0.33		0.92	0.71	0.62	-0.59	0.39	0.89	0.9	0.87	0.79	0.85	-0.29
Property Plant And Equipment Gross	0.89	0.84	0.54	0.91	0.89	0.63	0.88	0.89	0.85	0.84	0.97	0.76	0.88	0.51	0.92		0.79	0.56	-0.61	0.09	0.88	0.95	0.88	0.88	0.83	-0.32
Common Stock	0.68	0.73	0.37	0.82	0.73	0.55	0.68	0.75	0.7	0.66	0.77	0.68	0.69	0.37	0.71	0.79		0.49	-0.43	-0.08	0.69	0.79	0.72	0.86	0.62	-0.36
Short Long Term Debt Total	0.37	0.9	-0.28	0.69	0.81	1.0	0.38	0.37	0.76	0.25	0.4	0.94	0.28	-0.01	0.62	0.56	0.49		0.19	-0.17	0.4	0.7	0.82	0.47	0.22	-0.78
Net Debt	-0.84	-0.23	-1.0	-0.46	-0.38	0.1	-0.84	-0.46	-0.42	-0.83	-0.7	-0.02	-0.78	-0.7	-0.59	-0.61	-0.43	0.19		-0.47	-0.82	-0.48	-0.36	-0.52	-0.92	-0.34
Other Assets	0.34	-0.06	0.48	0.0	-0.02	-0.15	0.35	-0.06	0.1	0.24	0.18	-0.21	0.0	-0.15	0.39	0.09	-0.08	-0.17	-0.47		0.32	-0.02	-0.04	-0.06	0.41	0.39
Cash And Short Term Investments	1.0	0.73	0.77	0.8	0.83	0.48	1.0	0.63	0.79	0.93	0.88	0.56	0.9	0.64	0.89	0.88	0.69	0.4	-0.82	0.32		0.82	0.81	0.73	0.97	-0.19
Common Stock Total Equity	0.83	0.91	0.4	0.95	0.95	0.76	0.83	0.77	0.9	0.8	0.86	0.85	0.79	0.47	0.9	0.95	0.79	0.7	-0.48	-0.02	0.82		0.94	0.9	0.76	-0.43
Capital Surpluse	0.79	0.96	0.27	0.91	1.0	0.86	0.79	0.64	0.87	0.76	0.78	0.92	0.74	0.42	0.87	0.88	0.72	0.82	-0.36	-0.04	0.81	0.94		0.74	0.68	-0.65
Deferred Long Term Liab	0.74	0.74	0.46	0.83	0.75	0.54	0.74	0.86	0.75	0.73	0.85	0.68	0.71	0.36	0.79	0.88	0.86	0.47	-0.52	-0.06	0.73	0.9	0.74		0.7	-0.24
Net Invested Capital	0.98	0.59	0.88	0.74	0.7	0.31	0.98	0.6	0.73	0.93	0.85	0.39	0.88	0.68	0.85	0.83	0.62	0.22	-0.92	0.41	0.97	0.76	0.68	0.7		0.03
Short Long Term Debt	-0.13	-0.62	0.4	-0.4	-0.63	-0.75	-0.13	-0.23	-0.31	-0.2	-0.23	-0.79	-0.16	0.11	-0.29	-0.32	-0.36	-0.78	-0.34	0.39	-0.19	-0.43	-0.65	-0.24	0.03

Click cells to compare fundamentals

BioXcel Therapeutics Account Relationship Matchups

BioXcel Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	36.4M	219.9M	239.4M	205.9M	73.7M	100.3M
Total Current Liabilities	8.5M	11.8M	16.7M	32.9M	27.3M	28.6M
Total Stockholder Equity	26.9M	206.7M	221.7M	76.8M	(56.5M)	(53.7M)
Common Stock Shares Outstanding	16.3M	21.7M	26.4M	28.0M	29.1M	21.5M
Other Stockholder Equity	83.6M	345.5M	467.4M	488.3M	534.1M	560.8M
Total Liab	9.5M	13.2M	17.8M	129.1M	130.2M	136.7M
Total Current Assets	34.1M	217.1M	233.0M	202.9M	72.1M	98.2M
Property Plant Equipment	2.2M	1.3M	1.3M	1.1M	1.2M	855.5K
Other Current Liab	3.5M	6.9M	11.4M	22.3M	13.2M	8.5M
Net Tangible Assets	26.9M	206.7M	221.7M	76.8M	88.3M	89.5M
Property Plant And Equipment Net	2.2M	2.8M	2.5M	2.1M	1.5M	1.6M
Retained Earnings	(56.7M)	(138.9M)	(245.8M)	(411.5M)	(590.6M)	(561.1M)
Accounts Payable	5.0M	4.0M	4.7M	10.2M	13.7M	14.3M
Cash	32.4M	213.1M	233.0M	193.7M	65.2M	107.4M
Non Current Assets Total	2.3M	2.9M	6.5M	3.0M	1.6M	2.3M
Liabilities And Stockholders Equity	36.4M	219.9M	239.4M	205.9M	73.7M	112.8M
Non Current Liabilities Total	1.0M	1.4M	1.1M	96.2M	102.9M	108.1M
Other Current Assets	1.7M	6.9M	3.8M	6.9M	4.9M	3.4M
Property Plant And Equipment Gross	2.2M	2.8M	3.1M	2.9M	2.7M	1.9M
Common Stock	16K	18K	24K	28K	30K	31.5K
Net Debt	(31.4M)	(211.5M)	(231.6M)	(99.6M)	36.2M	38.0M
Cash And Short Term Investments	32.4M	213.1M	233.0M	193.7M	65.2M	122.7M
Common Stock Total Equity	16K	18K	24K	28K	32.2K	22.7K
Capital Surpluse	83.6M	345.5M	467.4M	488.3M	561.5M	589.6M
Net Invested Capital	26.9M	206.7M	221.7M	169.8M	44.1M	41.9M
Net Working Capital	25.6M	205.2M	220.1M	170.0M	44.9M	42.6M
Retained Earnings Total Equity	(56.7M)	(138.9M)	(245.8M)	(411.5M)	(370.4M)	(351.9M)

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:

How To Invest In BioXcel

Details

Is BioXcel Stock a good investment?

Details

What is BioXcel Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.04)

Revenue Per Share

0.074

Quarterly Revenue Growth

1.416

Return On Assets

(0.64)

Return On Equity

(17.67)

The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioXcel Total Assets vs Total Current Assets Analysis

Total Assets vs Total Current Assets

Total Assets vs Total Current Assets Correlation Analysis

Correlation Coefficient

Total Assets

Total Current Assets

BioXcel Therapeutics fundamental ratios Correlations

BioXcel Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioXcel Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Capital Surpluse	+ 1.0	Other Stockholder Equity
Short Long Term Debt Total	+ 1.0	Total Liab
Cash And Short Term Investments	+ 1.0	Total Current Assets
Net Invested Capital	+ 0.98	Total Assets

Net Debt	- 1.0	Total Stockholder Equity
Net Invested Capital	- 0.92	Net Debt
Net Debt	- 0.84	Total Current Assets
Net Debt	- 0.84	Total Assets
Net Debt	- 0.83	Net Tangible Assets
Cash And Short Term Investments	- 0.82	Net Debt